Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 known ✓ | P11362 | 2/20 | 0.62 |
| ▸ | FGFR3 known ✓ | P22607 | 1/20 | 0.62 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.59 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.52 |
| ▸ | BCR known ✓ | P11274 | 1/20 | 0.52 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.50 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | MMP3 | P08254 | 2/20 | 0.59 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.59 |
| ▸ | ABAT | P80404 | 1/20 | 0.56 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.55 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | AGXT | P21549 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2449967 | 0.98 | FGFR1 (0.64) | FGFR1FGFR2FGFR3MEN1ESR1 | |
| SCHEMBL3794460 | 0.86 | TAAR1 (0.70) | FGFR1FGFR2FGFR3ENPP2TAAR1 | |
| SCHEMBL2948809 | 0.84 | ENPP2 (0.76) | FGFR1FGFR2FGFR3ESR1KMT2A | |
| SCHEMBL28241991 | 0.84 | ENPP2 (0.53) | FGFR1FGFR2FGFR3MEN1ESR1 | |
| SCHEMBL28247640 | 0.84 | TAAR1 (0.74) | FGFR1FGFR2FGFR3ENPP2TAAR1 | |
| Hydrochloric Acid SCHEMBL29793666 | 0.84 | TAAR1 (0.67) | ENPP2TAAR1HRH3AGXTCFD | |
| Hydrochloric Acid SCHEMBL1237399 | 0.84 | TAAR1 (0.67) | ENPP2TAAR1HRH3AGXTCFD | |
| Hydrochloric Acid SCHEMBL2456572 | 0.83 | ABAT (0.80) | MEN1ESR1KMT2AENPP2ABAT | |
| SCHEMBL3791745 | 0.83 | LOXL2 (0.60) | FGFR1FGFR2FGFR3ENPP2TAAR1 | |
| Hydrochloric Acid SCHEMBL20497335 | 0.82 | HSD17B1 (0.68) | MEN1ESR1KMT2AENPP2ABAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730103-B1 | FORMAMIDE DERIVATIVES USEFUL AS ADRENOCEPTOR | PFIZER LTD (GB) | 2010-05-26 | — | — | EP | disclosed |
| US-7547731-B2 | Formamide derivatives for the treatment of diseases | PFIZER INC (US) | 2009-06-16 | — | — | US | disclosed |
| EP-1730141-B1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | PFIZER LTD (GB) | 2009-05-27 | — | — | EP | disclosed |
| US-7538141-B2 | Compounds for the treatment of diseases | PFIZER INC. | 2009-05-26 | — | — | US | disclosed |
| US-20080207689-A1 | Formamide Derivatives For The Treatment of Diseases | PFIZER INC | 2008-08-28 | — | — | US | disclosed |
| US-20080193988-A1 | Such as 2-(3-{2-[((2R)-2-{4-Benzyloxy-3-[(dimethylsulfonyl)amino]phenyl}-2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)amino]-2-methylpropyl}phenyl)-N-[(4'-hydroxybiphenyl-3-yl)methyl]-acetamide | GLADWELL IAIN ROBERT | 2008-08-14 | — | — | US | disclosed |
| EP-1907356-A2 | PROCESS FOR THE PREPARATION OF SULFONAMIDE DERIVATIVES | Pfizer Limited (GB) | 2008-04-09 | — | — | EP | disclosed |
| US-7241810-B2 | Formamide derivatives for the treatment of diseases | PFIZER INC (US) | 2007-07-10 | — | — | US | disclosed |
| WO-2007010356-A2 | PROCESS FOR THE PREPARATION OF SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2007-01-25 | — | — | WO | disclosed |
| EP-1730103-A1 | FORMAMIDE DERIVATIVES USEFUL AS ADRENOCEPTOR | Pfizer Limited (GB) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005092840-A1 | FORMAMIDE DERIVATIVES USEFUL AS ADRENOCEPTOR | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
| US-20050222128-A1 | Compounds for the treatment of diseases | PFIZER INC | 2005-10-06 | — | — | US | disclosed |
| US-20050215590-A1 | Formamide derivatives for the treatment of diseases | PFIZER LIMITED (GB) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207689-A1 | Formamide Derivatives For The Treatment of Diseases | FH, FAH, HRH4 | FGFR1 189/4885FGFR3 659/4885ESR1 3153/4885 |
| US-20080193988-A1 | Such as 2-(3-{2-[((2R)-2-{4-Benzyloxy-3-[(dimethylsulfonyl)amino]phenyl}-2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)amino]-2-methylpropyl}phenyl)-N-[(4'-hydroxybiphenyl-3-yl)methyl]-acetamide | NR4A1, CYP2A6, GPR6 | FGFR1 975/4885FGFR3 663/4885ESR1 110/4885 |
| US-20050222128-A1 | Compounds for the treatment of diseases | LTC4S, LTB4R2, CYP11B2 | FGFR1 1427/4885FGFR3 2653/4885ESR1 2490/4885 |
| US-20050215590-A1 | Formamide derivatives for the treatment of diseases | FH, FAH, HRH4 | FGFR1 189/4885FGFR3 659/4885ESR1 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.